FDA’s ODAC Votes 12 to 0 That MRD Is a Viable End Point in Myeloma Trials
The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end point in multiple myeloma clinical trials.
The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end point in multiple myeloma clinical trials.
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Exclusive: Donna Ockenden, who led a damning review into failings at Shrewsbury maternity services, described the support as “a house of cards” as she urged…
RAHWAY, N.J., May 01, 2024–Merck Announces KEYNOTE-811 Trial Met Dual Primary Endpoint as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or GEJ Cancer
Dr. Bose shares his vision for the future management of patients with intermediate myelofibrosis, including the unmet needs with current treatment options and the emerging…
Breast cancer cases are increasing among younger women, which means it now makes sense to start regular screening younger, a federal task force says.
The average total compensation for CEOs of the major health insurance companies increased 5.7% to $20.6 million last year, according to regulatory filings.
The world’s most influential people in health have made fresh discoveries, dreamed up novel treatments, and pioneered global victories over disease.
Location Henry B González Convention Center 900 E Market Street San Antonio, Texas Phone: (210) 207-8500 Program Schedule — Central Time 7:30 AM – 8:00…
Background Fee-for-service is a common payment model for remunerating general practitioners (GPs) in OECD countries. In Norway, GPs earn two-thirds of their income through fee-for-service,…
Finalized breast cancer screening recommendations from the United States Preventive Services Task Force suggest women aged 40 to 74 should get a mammogram every other…